On November 6, 2026, Pulse Biosciences, Inc. announced interim results from its PRECISE-BTN clinical study, which evaluates the effectiveness of its nPulse™ Vybrance™ Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study's results are significant as they indicate a high success rate in reducing nodule size and improving patient quality of life, potentially marking a breakthrough in non-invasive treatment options.

Pulse Biosciences, Inc. operates in the surgical and medical instruments sector, specifically focusing on innovative treatments using its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA) technology. The company is publicly traded on the Nasdaq under the ticker symbol PLSE. Recent filings include a 10-Q on November 5, 2026, and an 8-K on the same day, detailing updates on their clinical studies and financial performance.

The SEC filing reveals key findings from the interim dataset of 43 patients enrolled in the PRECISE-BTN study, treated at three clinical sites: Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine. Notably, 86% of patients achieved at least a 50% reduction in nodule volume at the six-month mark, with a median reduction of 72%. Furthermore, the ThyPRO-39 Overall Quality of Life Impact score improved by 78% from baseline.

Additional findings highlight that 82% of patients who reported neck pressure or fullness at baseline experienced complete resolution of symptoms by six months. Importantly, there were no serious adverse events reported during the study, underscoring the safety of the treatment.

The implications of these results extend beyond Pulse Biosciences, as they may influence patient treatment options and expectations in the surgical and medical instruments industry. The positive outcomes may prompt healthcare providers to consider the nPulse technology as a viable alternative to traditional surgical interventions for benign thyroid nodules.

Looking ahead, the company anticipates further developments as it continues to monitor the remaining patients in the study. The filing does not specify the timeline for subsequent updates or additional filings, but the interest surrounding the PRECISE-BTN study is expected to grow as more data becomes available.